ATHE (ATHE) Stock Price & Analysis
ATHE (ATHE) rose 10.00% to USD 4.29 as of June 10, 2026 at 02:36 UTC, according to Nexqual real-time market data.
ATHE last closed at USD 3.9; the session ranged USD 3.95–5.04 on volume of 1,591,394 shares. Market capitalization is $77.76M, with a 52-week range of USD 2.66–7 (NCM). Source: Nexqual, June 10, 2026 at 02:36 UTC.
Key Statistics (as of June 10, 2026 at 02:36 UTC)
| Price | USD 4.29 |
|---|---|
| Change | ▲ 10.00% (up) |
| Previous Close | USD 3.9 |
| Open | USD 4.05 |
| Day Range | USD 3.95 – 5.04 |
| 52-Week Range | USD 2.66 – 7 |
| Volume | 1,591,394 shares |
| Market Cap | $77.76M |
| Exchange | NCM |
Technical Analysis (ATHE)
Nexqual's technical model rates ATHE "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 52.97 (neutral) |
| vs SMA50 | Above (USD 4.21) |
| MACD | -0.08 (negative) |
Analyst Ratings (ATHE)
Wall Street analysts rate ATHE "None" based on 1 analysts, with a mean price target of USD 12 (range USD 12–12), per Nexqual as of June 10, 2026 at 02:36 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 12 |
| High Target | USD 12 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ATHE)
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financials & Fundamentals (ATHE)
| Total Revenue | $6.64M |
|---|---|
| Revenue Growth (YoY) | +74.60% |
| Gross Margin | +97.55% |
| Operating Margin | -372.59% |
| Profit Margin | -219.85% |
| ROE | -47.02% |
| Debt / Equity | 0.18 |
| Current Ratio | 21.98 |
| Total Cash | $49.20M |
| Total Debt | $98,449 |
| Free Cash Flow | $-10.61M |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Financial Health Score (ATHE)
Nexqual rates ATHE's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:36 UTC.
| Growth | Strong — Revenue +81% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $49M cash, no debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -47%, ROA -32.5% |
Ownership (ATHE)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +88.84% |
| Shares Outstanding | 18.13M |
| Float | 277,298 |
| Short % of Float | +0.05% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Leadership (ATHE)
ATHE is led by David A. Stamler (age 64), CEO & Director, per Nexqual as of June 10, 2026 at 02:36 UTC.
| CEO & Director | David A. Stamler (age 64) |
|---|---|
| CFO & Company Secretary | Abby Macnish Niven B.Com., B.Sc., C.F.A. (age 42) |
| Chief Scientific Advisor and Member of Research & Development Advisory Board | Rudolph Emile Tanzi (age 66) |
Major Backers & Investors (ATHE)
Notable institutional backers of ATHE include Twin Lakes Capital Management, LLC, HB Wealth Management, LLC, Morgan Stanley, according to Nexqual as of June 10, 2026 at 02:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Twin Lakes Capital Management, LLC | 0.77% |
| HB Wealth Management, LLC | 0.32% |
| Morgan Stanley | 0.32% |
| Greenleaf Trust | 0.18% |
| Citadel | 0.11% |
Source: Nexqual, June 10, 2026 at 02:36 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMRN | Immuron Limited | USD 1.19 | ▼ 4.8% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| RKTO | Rocket One Inc. | USD 1.28 | ▼ 15.23% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:36 UTC. This page is informational and not investment advice.